Sunovion Announces Collaboration With AMDA – The Society For Post-Acute And Long-Term Care Medicine

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sunovion Pharmaceuticals Inc. (Sunovion) announced today a collaboration with AMDA – The Society for Post-Acute and Long-Term Care Medicine, the only medical specialty society representing the community of over 50,000 medical directors, physicians, nurse practitioners, physician assistants and other practitioners working in various post-acute and long-term care (PA/LTC) settings. With support from Sunovion, 2,000 health care providers will receive resources on COPD management developed by the Society.

As an organization dedicated to ensuring patients receive the highest quality, compassionate PA/LTC, we are pleased to collaborate with Sunovion on the distribution of these resources,” said Christopher Laxton, CAE, Society Executive Director. “We believe this initiative will continue to define and improve quality professional development and evidence-based clinical guidance for the Society’s members and help the COPD patients for whom they care.”

Through this collaboration, health care professionals will be provided with educational materials that focus on preventing COPD morbidity and mortality; implementing best practices in transitions of care to and from the hospital and PA/LTC settings while recommending the use of maintenance therapies for stable COPD, including the appropriate use of long-acting bronchodilators and anti-inflammatory medications, as appropriate.

Sunovion’s support for Society resources represents our commitment to an important community of caregivers and patients in the post-acute and long-term care settings,” said Denise Strauss, Vice President, Marketing at Sunovion. “We are proud to contribute to the understanding of important advances and best practices in treating COPD.”

For more information please visit and

About COPD
Chronic obstructive pulmonary disease, also known as COPD, includes chronic bronchitis and emphysema, and is a progressive respiratory disease that causes worsening obstruction to airflow in the lungs over time.I Approximately 15.7 million adults in the U.S. report that they have been diagnosed with COPD.II It is estimated that several million more adults have undiagnosed COPD.III COPD is responsible for over 120,000 deaths per year, making it the third leading cause of death in the U.S.III COPD develops slowly and the symptoms often worsen over time, potentially limiting the ability to perform routine activities.I Symptoms of COPD include constant coughing, wheezing, shortness of breath, excess production of mucus in the lungs, the inability to breathe deeply and the feeling of being unable to breathe.III

About AMDA – The Society for Post-Acute and Long-Term Care Medicine
AMDA – The Society for Post-Acute and Long-Term Care Medicine is the only medical specialty society representing the community of over 50,000 medical directors, physicians, nurse practitioners, physician assistants, and other practitioners working in various post-acute and long-term care (PA/LTC) settings. The Society’s 5,500 members work in skilled nursing facilities, long-term care and assisted living communities, CCRCs, home care, hospice, PACE programs, and other settings.

The Society has two affiliate organizations. The American Board of Post-Acute and Long-Term Care Medicine runs a certification program for medical directors in PA/LTC, credentialing Certified Medical Directors (CMDs). The AMDA Foundation oversees awards, community outreach, education, and research with the mission to advance the quality of life for persons in PA/LTC through inspiring, educating, and recognizing future and current health care professionals.

About Sunovion Pharmaceuticals Inc. (Sunovion)
Sunovion is a global biopharmaceutical company focused on the innovative application of science and medicine to help people with serious medical conditions. Sunovion’s vision is to lead the way to a healthier world. The company’s spirit of innovation is driven by the conviction that scientific excellence paired with meaningful advocacy and relevant education can improve lives. With patients at the center of everything it does, Sunovion has charted new paths to life-transforming treatments that reflect ongoing investments in research and development and an unwavering commitment to support people with psychiatric, neurological, and respiratory conditions. Sunovion’s track record of discovery, development and commercialization of important therapies has included Brovana® (arformoterol tartrate), Latuda® (lurasidone HCI), and most recently Aptiom® (eslicarbazepine acetate).

Headquartered in Marlborough, Mass. Sunovion is an indirect, wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. Sunovion Pharmaceuticals Europe Ltd., based in London, England, Sunovion Pharmaceuticals Canada Inc., based in Mississauga, Ontario, and Sunovion CNS Development Canada ULC, based in Toronto, Ontario, are wholly-owned direct subsidiaries of Sunovion Pharmaceuticals Inc. Additional information can be found on the company’s web sites:, and Connect with Sunovion on Twitter, LinkedIn, Facebook and YouTube.

About Sumitomo Dainippon Pharma Co., Ltd.
Sumitomo Dainippon Pharma is among the top-ten listed pharmaceutical companies in Japan operating globally in major pharmaceutical markets, including Japan, the United States, China and the European Union. Sumitomo Dainippon Pharma aims to create innovative pharmaceutical products in the Psychiatry & Neurology area and the Oncology area, which have been designated as the focus therapeutic areas. Sumitomo Dainippon Pharma is based on the merger in 2005 between Dainippon Pharmaceutical Co., Ltd., and Sumitomo Pharmaceuticals Co., Ltd. Today, Sumitomo Dainippon Pharma has about 7,000 employees worldwide. Additional information about Sumitomo Dainippon Pharma is available through its corporate website at

BROVANA is a registered trademark of Sunovion Pharmaceuticals Inc.
LATUDA is a registered trademark of Sumitomo Dainippon Pharma Co., Ltd.
APTIOM is under license from BIAL.

Sunovion Pharmaceuticals Inc. is a U.S. subsidiary of Sumitomo Dainippon Pharma Co., Ltd.
© 2016 Sunovion Pharmaceuticals Inc.

For a copy of this release, visit Sunovion’s web site at

I National Heart, Lung and Blood Institute. What Is COPD? Available at Accessed: March 2, 2016
II MMWR: Morbidity and Mortality Weekly Report. Employment and Activity Limitations Among Adults with Chronic Obstructive Pulmonary Disease — United States, 2013. March 27, 2015; 64(11). Available at
III National Heart, Lung, and Blood Institute. “What is COPD?” Available at: Accessed: March 2, 2016


Sunovion Pharmaceuticals Inc.
Kristina Coppola, 508-787-4368
Senior Manager, Corporate Communications

Back to news